Clinical efficacy and safety of L-asparaginase combined with GDP regimen in treat-ment of patients with extranodal NK/T-cell lymphoma / 中国肿瘤临床

ABSTRACT

Objective:To evaluate the clinical efficacy and safety of L-asparaginase (L-ASP) combined with GDP regimen in initial treat-ment of patients with extranodal NK/T-cell lymphoma (ENKL). Methods:A total of 39 patients preliminarily diagnosed with nasal NK/T-cell lymphoma in Zhengzhou University Affiliated Cancer Hospital were retrospectively analyzed from January 2012 to January 2014. All patients received L-ASP combined with GDP chemotherapy. The efficacy of the treatment was observed (L-ASP 6000/m2, qod × 8;gemcitabine 1000 mg/m2, d1, 8;cisplatinum 90 mg/m2, d1;dexamethasone 10 mg, d1-4) every 21 days for one cycle. The efficacy and toxicity of the regimen were evaluated after therapy. Results:Of the 39 patients who received median six-cycle L-GDP regimen treat-ment, 24 achieved complete response, 7 had partial response, 6 had stable disease, and 2 had progressive disease. The rates of overall response (CR+PR), 2-year progression-free survival, and overall survival were 79.5%(31/39), 71.8%(28/39), and 87.2%(34/39), respec-tively. The primary side effects included gastrointestinal reaction, bone marrow suppression, and increased PT and APPT levels. All pa-tients tolerated and completed the therapy without termination of treatment and death. Conclusion:L-ASP combined with GDP regi-men is effective and safe and thus can be used for patients with ENKL.